There are 35 papers on volume depletion in aging research: 4 trials and 11 observational studies in people, 18 reviews. The newest story, Oct 4, 2026: “GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk”.
35 papers study it19 more mention it3 findings
6 new papers in 30 daysSee all 54
“volume depletion (OR 2.80, 95% CI 1.82-4.32, p = 0.000)”
Ertugliflozin
upin humans1
Ertugliflozin increases volume depletion in humans (compared with non-ertugliflozin treatment).
“In patients aged 65 years or older the incidences of volume depletion AEs and genital mycotic infection were higher with ertugliflozin than with non-ertugliflozin.”
Human trialcompared with non-ertugliflozin treatment
Diabetes, obesity & metabolism
Semaglutide
downin humans1
Semaglutide is linked with a lower risk of volume depletion in adults with ADPKD.
“Semaglutide use was also associated with lower incidences of volume depletion and all-cause mortality.”
Humansin adults with ADPKD
Science progress
SGLT2 inhibitors
upin humans1OR 2.8
SGLT2 inhibitors raise the risk of volume depletion in patients aged 65 years and older compared with under 65 years (OR 2.80, 95% CI 1.82-4.32).
“volume depletion (OR 2.80, 95% CI 1.82-4.32, p = 0.000)”
Human trialin patients aged 65 years and older compared with under 65 years
Endocrine journal
Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.Adding a GLP-1 receptor agonist was linked to lower rates of major adverse kidney events (HR 0.70) compared with SGLT2 inhibitor monotherapy over 12 months.